Study record

Exploring the therapeutic potential of MOTS-c in age-related macular degeneration: from cellular responses to patient-derived cybrids

Mohtashami Z, Schneider K, Azimi R et al. · Hum Cell · 2025

CellsMOTS-c administeredEvidence tier D
PubMed 39961901doi:10.1007/s13577-025-01188-wCompare with another study

What this study reported

Reported concentration-dependent effects of MOTS-c on apoptosis, inflammation and mitochondrial biogenesis gene expression in differentiated ARPE-19 cells, with lower concentrations producing larger effects than higher ones and no significant effect on ROS or NRF1. Responses differed between wild-type and differentiated cells and between cybrids from patients with age-related macular degeneration and age-matched controls.

Limitations

Transformed retinal cell line and cybrid models with chemically induced hypoxia; gene expression endpoints without functional visual outcomes; sample and replicate numbers not reported.

Study record

Annotated fields for this study
Study modelCell study (in vitro)
Substance studiedMOTS-c administeredSynthetic MOTS-c was given to cells, animals or people.
Specieshuman
System studiedWild-type and differentiated ARPE-19 retinal pigment epithelial cells and cybrids from patients with age-related macular degeneration and age-matched controls
PopulationNot reported
DesignCell culture experiments
Sample size as reportedNot reported
Control groupage-matched control cybrids and untreated cells
Route (data field only)in-culture
Endpoints measuredcell survival; apoptosis gene expression (CASP3, CASP9); mitochondrial biogenesis genes (TFAM, PGC-1α); AMPK expression; ROS levels
Pathways measuredApoptosis · SIRT1 / PGC-1α / biogenesis · AMPK signalling
Research areasAging · Mitochondrial biology
Evidence tierD — Cell, tissue or analytical
Publication typesJournal Article

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Direct
Model applicability
Cellular
Sample size
Not reported
Controls
Appropriate
Outcome validity
Exploratory
Support for its own conclusion
Weak

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the published abstract.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.